“…Disease heterogeneity is a characteristic feature of CTCL [ 93 , 97 , 98 , 99 , 100 , 101 ] even at the single-cell level [ 100 , 102 , 103 , 104 , 105 ], which has hampered the unraveling of the etiology and pathogenesis and has been a complicating factor in the development of novel therapies. Although high sun exposure is associated with a lower risk of developing MF in Caucasians [ 106 ], and heliotherapy (the use of natural sunlight for the treatment—also named climate therapy) [ 107 , 108 ] and phototherapy/photochemotherapy have beneficial effects on CTCL skin lesions [ 84 , 109 ], other studies indicate that UV light is also a driver of mutations in CTCL [ 110 , 111 , 112 , 113 ]. Thus, a large part of the mutational burden in MF and SS was linked to a UV signature, which was also observed in CD4 + T cells isolated from the blood of SS patients [ 111 , 112 , 113 ].…”